Tabula Rasa HealthCare (TRHC) Now Covered by Analysts at William Blair

William Blair assumed coverage on shares of Tabula Rasa HealthCare (NASDAQ:TRHC) in a research report report published on Monday morning. The firm issued an outperform rating on the stock.

Other equities analysts have also issued reports about the company. UBS raised their target price on Tabula Rasa HealthCare from $18.00 to $25.00 and gave the company a buy rating in a report on Wednesday, August 30th. BidaskClub lowered Tabula Rasa HealthCare from a strong-buy rating to a buy rating in a research note on Wednesday, December 6th. Wells Fargo & Company lowered Tabula Rasa HealthCare from an outperform rating to a market perform rating and lifted their price objective for the stock from $17.00 to $21.00 in a research note on Thursday, September 7th. ValuEngine upgraded Tabula Rasa HealthCare from a sell rating to a hold rating in a research note on Saturday, September 30th. Finally, Zacks Investment Research lowered Tabula Rasa HealthCare from a strong-buy rating to a hold rating in a research note on Friday, November 10th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $28.25.

Tabula Rasa HealthCare (TRHC) traded down $0.01 during midday trading on Monday, reaching $28.59. The company’s stock had a trading volume of 153,500 shares, compared to its average volume of 105,992. Tabula Rasa HealthCare has a one year low of $11.59 and a one year high of $36.80. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.02. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The company had revenue of $33.27 million for the quarter, compared to analyst estimates of $31.76 million. During the same period last year, the company earned $0.06 earnings per share. The business’s revenue was up 37.6% compared to the same quarter last year. analysts anticipate that Tabula Rasa HealthCare will post 0.05 earnings per share for the current fiscal year.

In related news, insider Orsula V. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $26.68, for a total transaction of $213,440.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Orsula V. Knowlton sold 123,000 shares of Tabula Rasa HealthCare stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $25.97, for a total value of $3,194,310.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 423,000 shares of company stock worth $10,925,950. 45.80% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Paradigm Capital Management Inc. NY grew its position in Tabula Rasa HealthCare by 3.4% during the third quarter. Paradigm Capital Management Inc. NY now owns 80,000 shares of the company’s stock worth $2,139,000 after buying an additional 2,644 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in Tabula Rasa HealthCare by 108.5% during the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after purchasing an additional 4,232 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Tabula Rasa HealthCare by 79.8% during the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock valued at $341,000 after purchasing an additional 5,668 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Tabula Rasa HealthCare by 60.2% during the second quarter. California State Teachers Retirement System now owns 16,500 shares of the company’s stock valued at $248,000 after purchasing an additional 6,200 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Tabula Rasa HealthCare by 47.2% during the second quarter. Bank of New York Mellon Corp now owns 19,412 shares of the company’s stock valued at $293,000 after purchasing an additional 6,228 shares in the last quarter. 31.85% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/12/tabula-rasa-healthcare-trhc-now-covered-by-analysts-at-william-blair.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply